You are viewing the site in preview mode

Skip to main content

Advertisement

Clinical/Translational Cancer Immunotherapy

Section edited by James L. Gulley, MD, PhD and Douglas G. McNeel, MD, PhD

First-in-man clinical trials (prospective clinical data only); phase II/III clinical studies; immune monitoring investigations; tumor microenvironment; combination therapies; and cell therapies.

Page 1 of 5

  1. Content type: Research article

    Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, we investigated the potential of CUP f...

    Authors: Koji Haratani, Hidetoshi Hayashi, Takayuki Takahama, Yasushi Nakamura, Shuta Tomida, Takeshi Yoshida, Yasutaka Chiba, Takahiro Sawada, Kazuko Sakai, Yoshihiko Fujita, Yosuke Togashi, Junko Tanizaki, Hisato Kawakami, Akihiko Ito, Kazuto Nishio and Kazuhiko Nakagawa

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:251

    Published on:

  2. Content type: Research article

    Antibody-drug conjugates (ADCs) targeting the RON receptor, a tumorigenic factor contributing to cancer malignancy, has been considered as a novel strategy for cancer therapy. Here we describe a humanized anti...

    Authors: Xiang-Min Tong, Liang Feng, Sreedhar Reddy Suthe, Tian-Hao Weng, Chen-Yu Hu, Yi-Zhi Liu, Zhi-Gang Wu, Ming-Hai Wang and Hang-Ping Yao

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:250

    Published on:

  3. Content type: Research article

    PD-1/PD-L1 blockade has received approval for clinical application due to its encouraging benefit with improving prognosis in selected populations. Unfortunately, the response to immunotherapy for many patient...

    Authors: Fan Luo, Min Luo, Qi-Xiang Rong, Hong Zhang, Zhen Chen, Fang Wang, Hong-Yun Zhao and Li-Wu Fu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:245

    Published on:

  4. Content type: Research article

    Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation m...

    Authors: Stefanie R. Mullins, John P. Vasilakos, Katharina Deschler, Iwen Grigsby, Pete Gillis, Julius John, Matthew J. Elder, John Swales, Elina Timosenko, Zachary Cooper, Simon J. Dovedi, Andrew J. Leishman, Nadia Luheshi, James Elvecrog, Ashenafi Tilahun, Richard Goodwin…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:244

    Published on:

  5. Content type: Research article

    Tumors can employ different mechanisms to evade immune surveillance and function. Overexpression of co-inhibitory ligands that bind to checkpoint molecules on the surface of T-cells can greatly impair the func...

    Authors: Shiran Hoogi, Vasyl Eisenberg, Shimrit Mayer, Astar Shamul, Tilda Barliya and Cyrille J. Cohen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:243

    Published on:

  6. Content type: Research article

    The gut microbiome impacts the efficacy of immune checkpoint inhibitor (ICI) therapy and the development of ICI-mediated diarrhea and/or colitis (IMDC). Antibiotic therapy,especially that with anaerobic activity,...

    Authors: Hamzah Abu-Sbeih, Lauren Nicholas Herrera, Tenglong Tang, Mehmet Altan, Anne-Maria P. Chaftari, Pablo C. Okhuysen, Robert R. Jenq and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:242

    Published on:

  7. Content type: Research article

    HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition...

    Authors: Marijo Bilusic, Christopher R. Heery, Julie M. Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marté, Julius Strauss, Margaret E. Gatti-Mays, Jeffrey Schlom and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:240

    Published on:

  8. Content type: Research article

    Preclinical evidence suggests that low-dose radiation may overcome the inhibitory effects of the tumor stroma and improve a tumor’s response to immunotherapy, when combined with high-dose radiation to another ...

    Authors: Hari Menon, Dawei Chen, Rishab Ramapriyan, Vivek Verma, Hampartsoum B. Barsoumian, Taylor R. Cushman, Ahmed I. Younes, Maria A. Cortez, Jeremy J. Erasmus, Patricia de Groot, Brett W. Carter, David S. Hong, Isabella C. Glitza, Renata Ferrarotto, Mehmet Altan, Adi Diab…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:237

    Published on:

  9. Content type: Research article

    T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantige...

    Authors: Qin Tan, Chaoting Zhang, Wenjun Yang, Ying Liu, Palashati Heyilimu, Dongdong Feng, Liying Xing, Yang Ke and Zheming Lu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:232

    Published on:

  10. Content type: Research article

    Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells that play an important role in immune evasion, PD-1/PD-L1 inhibitor tolerance and tumour progression. Therefore, MDSCs are potential targets...

    Authors: Wanfeng Gao, Xiaoyun Zhang, Wendong Yang, Daolei Dou, Heng Zhang, Yuanhao Tang, Weilong Zhong, Jing Meng, Yun Bai, Yanrong Liu, Lan Yang, Shuang Chen, Huijuan Liu, Cheng Yang and Tao Sun

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:231

    Published on:

  11. Content type: Short report

    T cell receptor (TCR) gene-engineered T cells have shown promise in the treatment of melanoma and synovial cell sarcoma, but their application to epithelial cancers has been limited. The identification of nove...

    Authors: Bridget Marcinkowski, Sanja Stevanović, Sarah R. Helman, Scott M. Norberg, Carylinda Serna, Benjamin Jin, Nikolaos Gkitsas, Tejas Kadakia, Andrew Warner, Jeremy L. Davis, Lisa Rooper and Christian S. Hinrichs

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:229

    Published on:

  12. Content type: Research article

    Samalizumab is a novel recombinant humanized monoclonal antibody that targets CD200, an immunoregulatory cell surface member of the immunoglobulin superfamily that dampens excessive immune responses and mainta...

    Authors: Daruka Mahadevan, Mark C. Lanasa, Charles Farber, Manjari Pandey, Maria Whelden, Susan J. Faas, Terrie Ulery, Anjli Kukreja, Lan Li, Camille L. Bedrosian, Xiaoping Zhang and Leonard T. Heffner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:227

    Published on:

  13. Content type: Short report

    Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of immune related adverse events (irAEs). Immune relat...

    Authors: Yousef R. Badran, Justine V. Cohen, Priscilla K. Brastianos, Aparna R. Parikh, Theodore S. Hong and Michael Dougan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:226

    Published on:

  14. Content type: Research article

    The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies.

    Authors: Aung Naing, Jeffrey Infante, Sanjay Goel, Howard Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:225

    Published on:

  15. Content type: Review

    As part of the 2018 Immunotherapy Bridge congress (November 28–29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy tod...

    Authors: Paolo A. Ascierto, Lisa H. Butterfield, Sandra Demaria, Robert L. Ferris, Gordon J. Freeman, Roger S. Lo, Alberto Mantovani, Paul Nathan, Omid Hamid, Katerina Politi and Igor Puzanov

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:221

    Published on:

  16. Content type: Research article

    Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosy...

    Authors: Kohei Shitara, Taroh Satoh, Satoru Iwasa, Kensei Yamaguchi, Kei Muro, Yoshito Komatsu, Tomohiro Nishina, Taito Esaki, Jun Hasegawa, Yasuyuki Kakurai, Emi Kamiyama, Tomoko Nakata, Kota Nakamura, Hayato Sakaki and Ichinosuke Hyodo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:219

    Published on:

  17. Content type: Research article

    Prostate cancer is poorly responsive to immune checkpoint inhibition, yet a combination with radiotherapy may enhance the immune response. In this study, we combined radiotherapy with immune checkpoint inhibit...

    Authors: Stephanie O. Dudzinski, Brent D. Cameron, Jian Wang, Jeffrey C. Rathmell, Todd D. Giorgio and Austin N. Kirschner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:218

    Published on:

  18. Content type: Research article

    Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can res...

    Authors: Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain and Tomoko Freshwater

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:212

    Published on:

  19. Content type: Short report

    Little is known about tumor-associated vasogenic edema in brain metastasis, yet it causes significant morbidity and mortality. Our purpose was to characterize edema in patients treated with anti-PD-1 and to st...

    Authors: Thuy T. Tran, Amit Mahajan, Veronica L. Chiang, Sarah B. Goldberg, Don X. Nguyen, Lucia B. Jilaveanu and Harriet M. Kluger

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:200

    Published on:

  20. Content type: Short report

    Strategies to improve activity of immune checkpoint inhibitors are needed. We hypothesized enhanced DNA damage by olaparib, a PARP inhibitor, and reduced VEGF signaling by cediranib, a VEGFR1–3 inhibitor, woul...

    Authors: Alexandra S. Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Stanley Lipkowitz, Jane B. Trepel, Rajni Sharma, Lekha Mikkilineni, Margaret Gatti-Mays, William D. Figg, Nicole D. Houston and Jung-Min Lee

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:197

    Published on:

  21. Content type: Research article

    Checkpoint inhibitors (CPI) have revolutionized the treatment of metastatic melanoma, but most patients treated with CPI eventually develop progressive disease. Local therapy including surgery, ablation or ste...

    Authors: Nicholas D. Klemen, Melinda Wang, Paul L. Feingold, Kirsten Cooper, Sabrina N. Pavri, Dale Han, Frank C. Detterbeck, Daniel J. Boffa, Sajid A. Khan, Kelly Olino, James Clune, Stephan Ariyan, Ronald R. Salem, Sarah A. Weiss, Harriet M. Kluger, Mario Sznol…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:196

    Published on:

  22. Content type: Research article

    Transient CD4+ T cell depletion led to the proliferation of tumor-specific CD8+ T cells in the draining lymph node and increased infiltration of PD-1+CD8+ T cells into the tumor, which resulted in strong anti-tum...

    Authors: Kohei Shitara, Satoshi Ueha, Shigeyuki Shichino, Hiroyasu Aoki, Haru Ogiwara, Tetsuya Nakatsura, Toshihiro Suzuki, Manami Shimomura, Toshiaki Yoshikawa, Kayoko Shoda, Shigehisa Kitano, Makiko Yamashita, Takayuki Nakayama, Akihiro Sato, Sakiko Kuroda, Masashi Wakabayashi…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:195

    Published on:

  23. Content type: Research article

    Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may arg...

    Authors: Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Darlene Mercieca, Marco W. J. Schreurs, Annemarie J. M. Wijkhuijs, Sander Bins, Esther Oomen-de Hoop, Reno Debets, Markus Joerger, Arlette Odink, Astrid A. M. van der Veldt, Cor H. van der Leest, Joachim G. J. V. Aerts, Ron H. J. Mathijssen and Stijn L. W. Koolen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:192

    Published on:

  24. Content type: Research article

    Glucocorticoid-induced TNFR-related protein (TNFRSF18, GITR, CD357), expressed by T cells, and its ligand (TNFSF18, GITRL), expressed by myeloid populations, provide co-stimulatory signals that boost T cell ac...

    Authors: David M. Richards, Viola Marschall, Katharina Billian-Frey, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Julian P. Sefrin, Matthias Schröder, Jaromir Sykora, Harald Fricke, Oliver Hill, Christian Gieffers and Meinolf Thiemann

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:191

    Published on:

  25. Content type: Research article

    Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy. As such, identifying strategies to bolster anti-t...

    Authors: A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor and Kunle Odunsi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:189

    Published on:

  26. Content type: Research article

    Immunotherapy has shown remarkable clinical promise in the treatment of various types of cancers. However, clinical benefits derive from a highly inflammatory mechanism of action. This presents unique challeng...

    Authors: Matthew R. Schuelke, Phonphimon Wongthida, Jill Thompson, Timothy Kottke, Christopher B. Driscoll, Amanda L. Huff, Kevin G. Shim, Matt Coffey, Jose Pulido, Laura Evgin and Richard G. Vile

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:188

    Published on:

  27. Content type: Hypothesis

    Tumor immunotherapy using gene-modified T cells has already met with considerable success in the treatment of metastatic melanoma and B cell lymphoma. With improving patient prognoses, new questions arise. In ...

    Authors: Cormac Cosgrove, Emilia R. Dellacecca, Joost H. van den Berg, John B. Haanen, Michael I. Nishimura, I. Caroline Le Poole and Hans E. N. Bergmans

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:186

    Published on:

  28. Content type: Short report

    We previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy. D...

    Authors: Silvia C. Formenti, Rachael E. Hawtin, Neha Dixit, Erik Evensen, Percy Lee, Judith D. Goldberg, Xiaochun Li, Claire Vanpouille-Box, Dörthe Schaue, William H. McBride and Sandra Demaria

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:177

    Published on:

  29. Content type: Research article

    DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune res...

    Authors: Alessandra Lopes, Sara Feola, Sophie Ligot, Manlio Fusciello, Gaëlle Vandermeulen, Véronique Préat and Vincenzo Cerullo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:174

    Published on:

  30. Content type: Short report

    Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have generated durable tumor ...

    Authors: Jaclyn LoPiccolo, Megan D. Schollenberger, Sumia Dakhil, Samuel Rosner, Osama Ali, William H. Sharfman, Ann W. Silk, Shailender Bhatia and Evan J. Lipson

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:170

    Published on:

  31. Content type: Research article

    Natural killer (NK) cells are an emerging new tool for cancer immunotherapy. To develop NK cell therapeutics from peripheral blood mononuclear cells (PBMCs) of healthy donors, substantial expansion of primary ...

    Authors: Yeon Ho Choi, Eun Jin Lim, Se Wha Kim, Yong Wha Moon, Kyung Soon Park and Hee-Jung An

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:168

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:211

  32. Content type: Research article

    The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is frequently asserted in the literature. However, specific cases were rarely described until 2018, when a wave...

    Authors: Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba and Rom S. Leidner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:165

    Published on:

  33. Content type: Research article

    The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies off...

    Authors: Louise M. E. Müller, Matthew Holmes, Joanne L. Michael, Gina B. Scott, Emma J. West, Karen J. Scott, Christopher Parrish, Kathryn Hall, Sina Stäble, Victoria A. Jennings, Matthew Cullen, Stewart McConnell, Catherine Langton, Emma L. Tidswell, Darren Shafren, Adel Samson…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:164

    Published on:

  34. Content type: Research article

    Cancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipo...

    Authors: Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, Nadejda V. Galeassi, Donna H. Deacon, Elizabeth M. Gaughan and Craig L. Slingluff Jr

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:163

    Published on:

  35. Content type: Research article

    Melanoma is a very aggressive skin tumor that can be cured when diagnosed and treated in its early stages. However, at the time of identification, the tumor is frequently in a metastatic stage. Intensive resea...

    Authors: Lise Pasquet, Elisabeth Bellard, Sophie Chabot, Bostjan Markelc, Marie-Pierre Rols, Justin Teissie and Muriel Golzio

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:161

    Published on:

  36. Content type: Research article

    Efficient identification of neoantigen-specific T-cell responses in epithelial ovarian cancer (EOC) remains a challenge. Existing investigations of spontaneous T-cell response to tumor neoepitope in EOC have t...

    Authors: Song Liu, Junko Matsuzaki, Lei Wei, Takemasa Tsuji, Sebastiano Battaglia, Qiang Hu, Eduardo Cortes, Laiping Wong, Li Yan, Mark Long, Anthony Miliotto, Nicholas W. Bateman, Shashikant B. Lele, Thinle Chodon, Richard C. Koya, Song Yao…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:156

    Published on:

  37. Content type: Research article

    Although accumulated evidence provides a strong scientific premise for using immune profiles to predict survival in patients with cancer, a universal immune profile across tumor types is still lacking, and how...

    Authors: Qingnan Zhao, Jiemiao Hu, Abhisek Mitra, Jeffry Cutrera, Wendong Zhang, Zhongting Zhang, Jun Yan, Xueqing Xia, Kris Michael Mahadeo, John Andrew Livingston, Richard Gorlick and Shulin Li

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:154

    Published on:

  38. Content type: Research article

    While significant strides in the treatment of metastatic bladder cancer have been made with immune checkpoint inhibitors, the treatment of carcinoma in situ and non-muscle invasive, non-metastatic (superficial...

    Authors: Y. Maurice Morillon II, Zhen Su, Jeffrey Schlom and John W. Greiner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:150

    Published on:

  39. Content type: Research article

    Pet dogs spontaneously develop lymphoma. An anthracycline-based multidrug chemotherapy regimen represents the treatment cornerstone; however, cure is rarely achieved. We have been treating dogs with B-cell lym...

    Authors: Laura Marconato, Luca Aresu, Damiano Stefanello, Stefano Comazzi, Valeria Martini, Roberta Ferrari, Fulvio Riondato, Nicole Rouquet, Patrick Frayssinet and Silvia Sabattini

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:146

    Published on:

  40. Content type: Short report

    Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients ...

    Authors: Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling and Howard L. Kaufman

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:145

    Published on:

  41. Content type: Research article

    D2C7-IT is a novel immunotoxin (IT) targeting wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins in glioblastoma. In addition to inherent tumoricidal activity, ...

    Authors: Vidyalakshmi Chandramohan, Xuhui Bao, Xin Yu, Scott Parker, Charlotte McDowall, Yen-Rei Yu, Patrick Healy, Annick Desjardins, Michael D. Gunn, Matthias Gromeier, Smita K. Nair, Ira H. Pastan and Darell D. Bigner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:142

    Published on:

  42. Content type: Research article

    The tumor immune microenvironment has become the focus of research in clear cell renal cell carcinoma (ccRCC) due to its important role in immune surveillance post nephrectomy. This study investigates the corr...

    Authors: Pooja Ghatalia, Jennifer Gordetsky, Fengshen Kuo, Essel Dulaimi, Kathy Q. Cai, Karthik Devarajan, Sejong Bae, Gurudatta Naik, Timothy A. Chan, Robert Uzzo, A. Ari Hakimi, Guru Sonpavde and Elizabeth Plimack

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:139

    Published on:

  43. Content type: Research article

    Human natural killer (NK) cell lines serve as an attractive source for adoptive immunotherapy, but NK-92 remains the only cell line being assessed in the clinic. Here, we established a novel NK cell line, NK10...

    Authors: Hyun Gul Yang, Moon Cheol Kang, Tae Yoon Kim, Injung Hwang, Hyun Tak Jin, Young Chul Sung, Ki-Seong Eom and Sae Won Kim

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:138

    Published on:

  44. Content type: Research article

    ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. T...

    Authors: Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Ann W. Silk, Nancy Chan, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Tina Mayer, Bruce G. Haffty, Jenna H. Newman, Salvatore M. Aspromonte, Praveen K. Bommareddy, Ricardo Estupinian, Charles B. Chesson…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:136

    Published on:

  45. Content type: Research article

    Immune checkpoint inhibitors (ICI) produce durable antitumor responses but provoke autoimmune toxicities, including uncommon but potentially devastating neurologic toxicities. The clinical features, including ...

    Authors: Douglas B. Johnson, Ali Manouchehri, Alexandra M. Haugh, Henry T. Quach, Justin M. Balko, Benedicte Lebrun-Vignes, Andrew Mammen, Javid J. Moslehi and Joe-Elie Salem

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:134

    Published on:

  46. Content type: Research article

    Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where Br...

    Authors: Kim M. van Pul, Ronald J.C.L.M. Vuylsteke, Rieneke van de Ven, Elisabeth A. te Velde, Emiel J. Th. Rutgers, Petrousjka M. van den Tol, Hein B.A.C. Stockmann and Tanja D. de Gruijl

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:133

    Published on:

  47. Content type: Research article

    Immune checkpoint inhibitors are not effective for pancreatic ductal adenocarcinoma (PDAC) as single agents. Vaccine therapy may sensitize PDACs to checkpoint inhibitor treatments. Annexin A2 (ANXA2) is a pro-...

    Authors: Victoria M. Kim, Alex B. Blair, Peter Lauer, Kelly Foley, Xu Che, Kevin Soares, Tao Xia, Stephen T. Muth, Jennifer Kleponis, Todd D. Armstrong, Christopher L. Wolfgang, Elizabeth M. Jaffee, Dirk Brockstedt and Lei Zheng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:132

    Published on:

  48. Content type: Research article

    The immunogenomic changes triggered by concurrent chemoradiation therapy (CCRT), a standard neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC), are unknown. We aimed to analyz...

    Authors: Sehhoon Park, Je-Gun Joung, Yang Won Min, Jae-Yong Nam, Daeun Ryu, Dongryul Oh, Woong-Yang Park, Se-Hoon Lee, Yoon La Choi, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park and Jong-Mu Sun

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:128

    Published on:

  49. Content type: Research article

    Recurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV)-driven disorder that causes substantial morbidity and can lead to fatal distal airway obstruction and post-obstructive pneumonias. Pat...

    Authors: Clint T. Allen, Sunmin Lee, Scott M. Norberg, Damian Kovalovsky, Hong Ye, Paul E. Clavijo, Siwen Hu-Lieskovan, Richard Schlegel, Jeffrey Schlom, Julius Strauss, James L. Gulley, Jane Trepel and Christian S. Hinrichs

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:119

    Published on:

  50. Content type: Research article

    Immune checkpoint inhibitors (ICIs) represent a promising novel class of cancer therapy, but immune-mediated adverse events can complicate ICI treatment. Acute cholecystitis in patients receiving ICI therapy h...

    Authors: Hamzah Abu-Sbeih, Cynthia Nguyen Tran, Phillip S. Ge, Manoop S. Bhutani, Mazen Alasadi, Aung Naing, Amir A. Jazaeri and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:118

    Published on:

Annual Journal Metrics

Advertisement